Skip to main content

PASG

Stock
Health Care
Biotechnology

Performance overview

PASG Price
Price Chart

Forward-looking statistics

Beta
1.69
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

Company info

SectorHealth Care
IndustryBiotechnology
Employees98
Market cap$73.0M

Fundamentals

Enterprise value-$13.4M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity53.77

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.02
Dividend per share—
Revenue per share—
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$3M
Put-call ratio—

Macro factor sensitivity

Growth+0.1
Credit+3.5
Liquidity-3.1
Inflation-1.2
Commodities+0.5
Interest Rates-3.2

Valuation

Dividend yield0.00%
PEG Ratio-0.92
Price to sales—
P/E Ratio-0.92
Enterprise Value to Revenue—
Price to book0.61

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend day—

News

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know

Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (March 7, 2025)
2 Stocks Under $3 Insiders Are Aggressively Buying

US crude oil futures traded higher on Friday. Investors, meanwhile, focused on some notable insider trades.

Benzinga (May 6, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free